Author

S. Froehling

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 5 Cell Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 5 Assay:bulk RNA-seq· 3 Research Focus:cell type annotation· 3 Approach:deep learning· 2 Approach:experimental assay· 2 Approach:statistical model· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:differential expression· 1

Frequent Co-Authors

C. Scholl· 2 shared A. Kuntze· 1 shared A. M. Krackhardt· 1 shared A. Mock· 1 shared A.-H. Maag· 1 shared B. Altvater· 1 shared B. C. Jones· 1 shared B. Haller· 1 shared

Activity by Year

2020-2024 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 7 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

C. Scholl

Mutual co-authors in cluster

Author profile →

6 papers

Recent·Most cited

Exploiting WEE1 kinase activity as FUS::DDIT3-dependent therapeutic vulnerability in myxoid liposarcoma

L. Heinst, K. S. Lee, R. Berthold, I. Isfort, S. Wosnig, A. Kuntze, S. Hafner, B. Altvater, C. Roessig, P. Aman, E. Wardelmann, C. Scholl, W. Hartmann, S. Froehling, M. Trautmann

This study identifies WEE1 kinase activity as a therapeutic target in FUS::DDIT3-driven myxoid liposarcoma by showing its role in replication stress tolerance and cell survival.

Clinical Cancer Research · Aug 29, 2024Peer-reviewedCancer Biology

Oncogenic RAS-Pathway Activation Drives Oncofetal Reprogramming and Creates Therapeutic Vulnerabilities in Juvenile Myelomonocytic Leukemia

M. Hartmann, M. Schoenung, J. Rajak, V. Maurer, L. Hai, K. Bauer, M. Hakobyan, S. Staeble, J. Langstein, L. Jardine, R. Roelz, S. Bohler, E. Khabirova, A.-H. Maag, D. Vonficht, , D. B. Lipka

This study identifies oncofetal reprogramming in juvenile myelomonocytic leukemia, linking RAS-pathway activation to fetal gene expression and revealing CD52 as a therapeutic target.

bioRxiv · Oct 27, 2023Cancer Biology

Cell division tracing combined with single-cell transcriptomics reveals new cell types and differentiation paths in the regenerating mouse lung

L. R. Martins, L. Sieverling, M. Michelhans, C. Schiller, C. Erkut, S. Triana, S. Froehling, L. Velten, H. Glimm, C. Scholl

bioRxiv · Jan 18, 2023Cell Biology

Proteogenomic analysis reveals RNA as an important source for tumor-agnostic neoantigen identification correlating with T-cell infiltration

C. Tretter, N. de Andrade Kraetzig, M. Pecoraro, S. Lange, P. Seifert, C. von Frankenberg, J. Untch, F. S. Dreyer, E. Braeunlein, M. Wilhelm, D. P. Zolg, T. Engleitner, S. Uhrig, M. Boxberg, K. Steiger, , A. M. Krackhardt

This study identifies RNA as a significant source of tumor-agnostic neoantigens, which correlate with T-cell infiltration in multiple cancer types.

bioRxiv · Sep 17, 2022Cancer Biology

Comprehensive analysis of mutational signatures in pediatric cancers

V. Thatikonda, S. M. A. Islam, B. C. Jones, S. N. Groebner, G. Warsow, B. Hutter, D. Huebschmann, S. Froehling, M. Blattner-Johnson, D. T. W. Jones, L. B. Alexandrov, S. M. Pfister, N. Jaeger

This study analyzes mutational signatures in pediatric cancers, finding fewer active signatures compared to adult cancers and linking specific signatures to TP53 mutations and chromothripsis.

bioRxiv · Sep 28, 2021Cancer Biology

Integrative kinomics reveals kinase-driven subtypes of gastric adenocarcinomas with sunitinib as a potential common inhibitor

M. J. Tapken, G. M. Haag, D. Jaeger, S. Froehling, A. Mock

bioRxiv · Feb 12, 2020 · PreprintCancer Biology